Heterogeneity of treatment effect of higher dose dexamethasone by geographic region in patients with COVID-19 and severe hypoxemia - A post hoc evaluation of the COVID STEROID 2 trial
Data Availability
Data are available upon reasonable request. Deidentified patient data will be made available beginning 6 months after publication of the study and ending at 2 years. All requests for data sharing must be accompanied by a formal request, a study proposal with clear statement of aims and hypotheses and a statistical analysis plan. All applications will be assessed by the COVID-STEROID 2 Trial Management Committee. Applications from investigators with suitable academic capability to conduct the proposed work will be given consideration. Any proposal will require approval from the ethics committee which approved the conduct of this trial prior to sharing of any patient data. If a proposal is approved, a signed data transfer agreement will be required before data sharing.
Subject Area
- Addiction Medicine (361)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2712)
- Dermatology (232)
- Emergency Medicine (409)
- Epidemiology (12355)
- Forensic Medicine (10)
- Gastroenterology (779)
- Genetic and Genomic Medicine (4202)
- Geriatric Medicine (394)
- Health Economics (694)
- Health Informatics (2716)
- Health Policy (1012)
- Hematology (367)
- HIV/AIDS (871)
- Medical Education (402)
- Medical Ethics (111)
- Nephrology (447)
- Neurology (3990)
- Nursing (216)
- Nutrition (589)
- Oncology (2103)
- Ophthalmology (598)
- Orthopedics (249)
- Otolaryngology (309)
- Pain Medicine (255)
- Palliative Medicine (77)
- Pathology (475)
- Pediatrics (1140)
- Primary Care Research (464)
- Public and Global Health (6615)
- Radiology and Imaging (1432)
- Respiratory Medicine (879)
- Rheumatology (417)
- Sports Medicine (349)
- Surgery (458)
- Toxicology (57)
- Transplantation (192)
- Urology (170)